SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, NC–(BUSINESS WIRE)–February 21, 2022–
United Therapeutics Corporation (Nasdaq: UTHR) today announced that it will release its fourth quarter and full year 2021 financial results before market open on Thursday, February 24, 2022.
United Therapeutics will host a public webcast on Thursday, February 24, 2022 at 9:00 a.m. EST. The webcast will be accessible via the United Therapeutics website at https://ir.unither.com/events-and-presentations. A replay of the webcast will be available for one week and accessible from the same location.
United Therapeutics: Enabling Inspiration
We draw on the strength of our research and development expertise and a distinctive entrepreneurial culture that encourages diversity, innovation, creativity, sustainability and, quite simply, fun. Since its inception, our mission has been to find a cure for pulmonary arterial hypertension and other life-threatening diseases. To this end, we have successfully obtained FDA approval for five drugs, we are still conducting new clinical trials, and we are working to create an unlimited supply of manufactured organs for transplantation.
We are the first publicly traded biotechnology or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public interest objective is provide a better future for patients through (a) the development of new pharmaceutical therapies; and (b) technologies that increase the availability of transplantable organs. At the same time, we seek to provide our shareholders with superior financial performance and our communities with earth-friendly energy use.
You can find out more about what it means to be a PBC here: unither.com/PBC.
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among other things, statements relating to our mission to find a cure for pulmonary hypertension and other life-threatening diseases, our ongoing and future clinical trials and other research and development efforts, and our goals of furthering our public interest goal, providing financial performance superior to shareholders and provide our communities with earth-sensitive energy use. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, which could cause actual results to differ materially from anticipated results. Accordingly, these forward-looking statements are qualified by the cautionary, cautionary and risk factors set forth in our periodic reports and filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K. , quarterly reports on Form 10-Q and current reports on Form 8-K. We claim the safe harbor protections contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We provide this information as of February 21, 2022, and undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or otherwise. raison.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220221005093/en/
CONTACT: Dewey Steadman at (202) 919-4097
Email: [email protected]
KEYWORD: NORTH CAROLINA MARYLAND UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTHCARE OTHER HEALTHCARE CLINICAL TRIALS PHARMACEUTICAL CARDIOLOGY BIOTECHNOLOGY
SOURCE: United Therapeutics Corporation
Copyright BusinessWire 2022.
PUBLISHED: 02/21/2022 06:00 / DISK: 02/21/2022 06:02